Double-blind crossover trial comparing systemic chromosome-carboxylic acid with placebo in patients with atopic dermatitis.
35 adult patients with atopic dermatitis were included in a double-blind crossover trial comparing chromone-2-carboxylic acid, FPL 57787 18 mg x 4, with placebo. Each treatment period lasted for 6 weeks with clinical assessment every 3 weeks. 28 patients completed 3 weeks of each period. Significant differences at the 5% level in favour of FPL 57787 were seen in the group starting on placebo. 17 patients completed the study. After 6 weeks there were no significant differences. 10 patients experienced dyspeptic side-effects. Further studies are warranted on clearly allergic sub-groups of atopic dermatitis patients.
D000293:Adolescent; D002867:Chromones / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000175:diagnosis / Q000188:drug therapy*; D004311:Double-Blind Method; D004415:Dyspepsia / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D010349:Patient Compliance; D010919:Placebos / Q000627:therapeutic use*; D011537:Pruritus / Q000188:drug therapy
D002867:Chromones; D010919:Placebos; C020486:proxicromil